Antipsychotic drugs: Risk factors for diabetes;Les médicaments antipsychotiques: Facteurs de risque de diabète

Presse Medicale

Volumn 32, Issue 34, 2003, Pages 1612-1617

  Stip, Emmanuel ^a   Tranulis, Constantin ^b   Légaré, Nancy ^b   Poulin, Marie Josée ^b  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; THIORIDAZINE;

CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; HUMANS; OBESITY; RISK FACTORS; SCHIZOPHRENIA;

EID: 0142153204     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Stip E. Happy Birthday neuroleptics! 50 years later: la folie du doute. Eur Psychiatry 2002; 17: 115-19.
2. Stip E, Tranulis C, Légaré N, Poulin MJ. Diabète et schizophrénie. Presse Med 2003; 32: 1566-71.
3. Kasanin J. The blood sugar curve in mental disease. The schizophrenic (dementia praecox) groups. Arch Neurol Psychiatry 1926; 16: 414-19.
4. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156: 1417-20.
5. Lilliker S. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry 1980; 21: 270-5.
6. Erle G, Basso M, Federspil G, Sicolo N, Scandellad C. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacol 1977; 11: 15-18.
7. Korenyi C, Lowenstein B. Chlorpromazine induced diabetes. Dis Nerv Syst 1968; 29: 827-8.
8. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968; 124: 978-82.
9. Hagg S, Joelsson L, Mjorndal T, Spigset O, Oja G, Dahlqvist R. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59: 294-9.
10. Isojarvi J, Laatikainen T, Knip M, Pakarinen A, Juntunen K, Myllyla V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579-84.
11. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16: 63-73.
12. Liebzeit K, Markowitz J, Caley C. New onset diabetes and atypical anti psychotics. Eur Neuropsychopharmacol 2001; 11: 25-32.
13. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 1999; 60: 556-7.
14. Procyshyn RM, Pande S, Tse G. New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry 2000; 45: 668-9.
15. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? Psychosomatics 2000; 41: 369-70.
16. Haupt D, Newcomer J. Risperidone-associated diabetic ketoacidosis. Psychosomatics 2001; 42: 279-80.
17. Mohan D, Gordon H, Hindley N, Barker A. Schizophrenia and diabetes mellitus. Br J Psychiatry 1999; 174: 180-1.
18. Wirshing D, Pierre J, Eyeler, J, Weinbach J, Wirshing W. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001; 50: 148-9.
19. Wirshing D, Spellberg B, Erhart S, Marder S, Wirshing W. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778-83.
20. Cavazzoni P, Baker RW, Kwong K, et al. A pharmacoepidmiological study of diabetes mellitus and antipsychotic treatment in the United States. 41st New Clinical Drug Evaluation Unit. Phoenix, AZ, 2001
21. Mahmoud R, Gianfrancesco F, Grogg A, Nasrallah HA. Differential effects of antipsychotics on type 2 diabetes: Findings from a large health plan database [abstract]. 39th Annual Meeting Amer College Neuropsychopharmacology, Puerto Rico, December 10-14: www.abstracts-on.line.com
22. Allison DB, Cavazzoni P, Beasley CM et al. Random blood glucose levels inpatients with schizophrenia treated with typical and atypical antipsychotic agents: An analysis of data from double-blind, randomized, controlled clinical trials [abstract). International Congress on Schizophrenia Research. Whistler, BC, Canada, 2001
23. Caro J, Ward A, Levinton C, Robinson K, Kopala L. The risk of developing diabetes in users of atypical antipsychotics [abstract). 39th Annual Meeting Amer College Neuropsychopharmacology, Puerto Rico, December 10-14: www.abstracts-on-line.com
24. Wang PS, Glynn RJ, Ganz Da, Schneeweiss S, Levin R, Avorn J. Clozapine use and the risk of diabetes mellitus. J Clin Psychopharmacol. 2002; 22: 236-43.
25. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337-45.
26. Meyer JM. A retrospective comparison of weight lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425-33.
27. Serniak MJ, Lestie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatement of schizophrenia. Am J Psychiatry 2002; 159: 561-6.
28. Koro CE, Fedder DO, L'Italien GJ et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325: 243-7.
29. Allison D, Casey D. Antipsychotic-induced weight gain: A review of the literature. J Clin Psychiatry 2001; 62 Suppl 7:22-31.
30. Allison D, Mentore J, Heo M et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
31. Henderson DC Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157: 975-81.
32. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Daliman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374: 542-6
33. Wozniak KM, Linnoila M. Hyperglycemic properties of serotonin receptor antagonists. Life Sci 1991; 49: 101-9.
34. Uvnas-Moberg K, Hillegaart V, Alster P, Ahlenius S. Effects of 5-HT agonists, selective for different receptor subtypes, on oxytocin, CCK, gastrin and somatostatin plasma levels in the rat. Neuropharmacology 1996; 35: 1635-40.
35. Baudde V, Chaouloff F. Influence of catecholaminergic and serotonergic receptor antagonists on the hyperglycaemic response to the neuroglucopaenic agent 2-deoxy-D-glucose. Neuropharmacology 1991; 30: 599-605.
36. Sorenson RL, Brelie TC. Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res 1997; 29: 301-7.
37. Procyshyn R, Kennedy N, Tse G, Thompson B. Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001; 46: 334-9.
38. Rittmannsberger H, Meise U, Schauflinger K, Horvath E, Donat H, Hinterhuber H. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999; 14: 33-40.
39. Williams C, Johnstone B, Kesterson J, Javor K, Schmetzer A. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia, Med Care 1999; 37: AS81-6.
40. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry 2001; 46: 549-55.
41. Fontaine K, Heo M, Hardgan E et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001; 101: 277-88.
42. Nasrallah HA, White T, Nasrallah AT. Lower mortality in geriatric patients receiving atypical antipsychotics compared to haloperidol [abstract]. 39th Annual Meeting Amer College Neuropsychopharmacology, Puerto Rico, December 10-14. www.abstracts-on-line.com.abstract/ACNP/, 2000.
43. Bettinger TL, Mendelson SC, Dorson PG, Crismon ML. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34: 865-7.
44. Rotatori A, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self control program. Psychol Rep 1980; 46: 483-6.
45. Knox J. A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry 1980; 136: 287-9.
46. Klein B, Simon W, Steele R, Primavera L. Reinforcement and weight loss in schizophrenics. Psychol Rep 1972; 30: 581-2.
47. Ball M, Coons V, Buchana R. A traditional weight management, education, and support group program for treatment of olanzapine related weight gain. New Clinical Drug Evaluation Unit. Boca Raton, 1999
48. Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998; 43 Suppl 2: 255-405.
49. Everhart J, Pettitt D, Bennett P, Knowler W. Duration of obesity increases the incidence of NIDDM. Diabetes 1992; 41: 23540.
50. Wannamethee S, Shaper A. Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care 1999; 22: 1266-72.
51. Weyer C, Hanson K, Bogardus C, Pratley R. Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of bodyweight. Diabetologia 2000; 43: 36-46.
52. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 2000; 20: 716-17.
53. Dursun S, Devarajan S, Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000; 45: 198.
54. Gordon A, Price L. Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999; 156: 968-9.
55. Khan A, Faught E, Gilliam F, Kuzniecky R. Acute psychotic symptoms induced by topiramate. Seizure 1999; 8: 235-7.
56. Breier A, Tanaka Y, Roychowdhury S, Clark S. Nizatidine for the prevention of olanzapine-associated weight gain in schizophrenia and related disorders, a randomized controlled double blind study [abstract]. International Congress on Schizophrenia Research. Whistler, BC, Canada, 2001.
57. Morrison JA, Cottingham EM, Barton B. Metformin for Weight Loss in Pediatric Patients Taking Psychotropic Drugs. Am J Psychiatry 2002; 159: 655-7.
58. Serniak MJ, Lestie DL, Alarcon RD, Losonay MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatement of schizophrenia. Am J Psychiatry 2002; 159: 561-6.